Healthcare Services

Cholangiocarcinoma Market Future Outlook Showing Expansion Toward $1.14 Billion by 2030

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Cholangiocarcinoma Market During 2026–2030?

The cholangiocarcinoma market size has witnessed swift expansion in recent years. It is forecast to grow from $0.62 billion in 2025 to $0.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.1%. The historical growth of the market can be ascribed to factors like the increasing incidence of bile duct cancers, limited availability of curative treatments, adoption of chemotherapy as standard care, expansion of oncology treatment centers, and growing oncology drug pipelines.

The cholangiocarcinoma market is projected to experience swift expansion in the coming years. This market is anticipated to reach a valuation of $1.14 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.8%. This expansion during the projection period stems from factors such as the increasing creation of targeted oncology medications, the growing implementation of personalized medicine strategies, the broadened scope of clinical trials for rare cancers, augmented investment in oncology research, and a heightened emphasis on diagnosing the condition at early stages. Key trends identified for this forecast period encompass the increasing embrace of targeted drug treatments, a surge in the application of combination chemotherapy protocols, a sharpened focus on precision oncology, an enlarged scope for immunotherapy investigations, and an intensified commitment to early diagnosis.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21139&type=smp

What Underlying Factors Are Accelerating The Growth Of The Cholangiocarcinoma Market?

The escalating prevalence of liver disease is projected to fuel the expansion of the cholangiocarcinoma market. Liver disease encompasses conditions that compromise the liver’s normal structure or function, including hepatitis, cirrhosis, fatty liver disease, and liver cancer. The incidence of liver disease is on the rise, attributed to escalating risk factors such as obesity, diabetes, alcohol consumption, and viral hepatitis infections. Notably, liver disease, especially in its forms of chronic inflammation and cirrhosis, heightens the risk of cholangiocarcinoma by encouraging damage to bile ducts and the transformation of cells into malignant ones. As an illustration, in December 2024, data from the Office for Health Improvement and Disparities, a UK-based government agency, indicated that premature deaths from alcoholic liver disease climbed by 3.6% to 5,984 in 2023, an increase from 5,776 in 2022. Consequently, the growing incidence of liver disease is a key driver for growth within the cholangiocarcinoma market.

How Are The Various Segments Of The Cholangiocarcinoma Market Categorized?

The cholangiocarcinoma market covered in this report is segmented –

1) By Cancer: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma

2) By Product: Capecitabine, 5-Fluorouracil, Oxaliplatin, Gemcitabine, Cisplatin

3) By Therapy: Targeted Drug Therapy, Chemotherapy, Immunotherapy

4) By Route Of Administration: Oral, Subcutaneous, Intravenous

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-Commerce

Subsegments:

1) By Intrahepatic Cholangiocarcinoma: Peripheral Intrahepatic Cholangiocarcinoma, Mass-Forming Intrahepatic Cholangiocarcinoma

2) By Extrahepatic Cholangiocarcinoma: Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma

What Key Trends Are Influencing The Development Of The Cholangiocarcinoma Market?

Leading companies active in the cholangiocarcinoma market are prioritizing the development of innovative treatments, such as targeted therapies, to enhance patient outcomes. Targeted therapies are designed to specifically address genes, proteins, or molecules that contribute to cancer cell growth. These therapeutic approaches function by interrupting the processes that allow cancer to proliferate, aiming to halt tumor expansion, minimize side effects, and improve overall treatment effectiveness. For example, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, introduced LYTGOBI (futibatinib), an FGFR inhibitor, for managing unresectable biliary tract cancer with FGFR2 gene fusions. This medication is engineered to selectively and irreversibly inhibit FGFR signaling, thereby aiding in slowing tumor growth and improving results for patients with cholangiocarcinoma (iCCA) that has advanced following chemotherapy.

Which Major Firms Influence Developments In The Cholangiocarcinoma Market?

Major companies operating in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., Taiho Pharmaceutical Co. Ltd.

Read the full cholangiocarcinoma market report here:

https://www.thebusinessresearchcompany.com/report/cholangiocarcinoma-global-market-report

Which Region Is Projected To Dominate The Cholangiocarcinoma Market During The Forecast Period?

North America was the largest region in the cholangiocarcinoma market in 2025. The regions covered in the cholangiocarcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cholangiocarcinoma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21139&type=smp

Browse Through More Reports Similar to the Global Cholangiocarcinoma Market 2026, By The Business Research Company

Chlamydia Infection Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/chlamydia-infection-diagnostics-global-market-report

Std Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/std-diagnostics-global-market-report

Chlamydia Infection Diagnostics And Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/chlamydia-infection-diagnostics-and-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795